Evofem Biosciences

Last month the FDA greenlit four oncology approvals early and the first GnRH antagonist in uterine fibroids.

Astrazeneca’s Lynparza is due US approval decisions in prostate and ovarian cancers, while Bristol's Opdivo’s fate will be determined in lung cancer.

June 07, 2019

December 18, 2018

November 23, 2018

A two-for-one holiday sale is coming for Hetlioz and tradipitant, and Evofem hopes to confirm its contraceptive gel's effectiveness.

Evaluate